Drug guidance
Ruxolitinib for treating graft-versus-host disease
Condition
Blood and Immune System
4 June 2024
Published on 04 Jun 2024
Last Updated on 04 Jun 2024
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
Ruxolitinib 5 mg, 15 mg and 20 mg tablets for treating grades II to IV acute graft-versus-host disease (GVHD) in patients who have an inadequate response to corticosteroids.
Funding status
Ruxolitinib 5 mg, 15 mg and 20 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2024.
MAF assistance does not apply to ruxolitinib for treating moderate to severe chronic GVHD in patients who have an inadequate response to corticosteroids.
Ruxolitinib for treating graft-versus-host disease (Published 4 Jun 24) [PDF, 125 KB]
PES Ruxolitinib for treating graft-versus-host disease (Published 4 Jun 24) [PDF, 109 KB]